Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish Sells 9,302 Shares

Key Points

• Scott Lish, COO of Alphatec Holdings, sold 9,302 shares of stock at an average price of $16.00, resulting in a total transaction value of $148,832.
• Following the recent trades, Lish's ownership in the company decreased by 1.38%, leaving him with 665,030 shares valued at approximately $10.6 million.
• Alphatec's stock price recently reached $15.70, with a market cap of $2.32 billion and a projected -1.08 earnings per share for the current fiscal year.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 9,302 shares of the firm's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $16.00, for a total transaction of $148,832.00. Following the transaction, the chief operating officer directly owned 665,030 shares in the company, valued at approximately $10,640,480. The trade was a 1.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Scott Lish also recently made the following trade(s):

• On Tuesday, August 5th, Scott Lish sold 16,666 shares of Alphatec stock. The shares were sold at an average price of $15.00, for a total value of $249,990.00.
• On Monday, August 4th, Scott Lish sold 17,857 shares of Alphatec stock. The shares were sold at an average price of $14.00, for a total value of $249,998.00.
• On Friday, August 1st, Scott Lish sold 36,081 shares of Alphatec stock. The shares were sold at an average price of $12.53, for a total value of $452,094.93.
• On Thursday, July 10th, Scott Lish sold 3,982 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total value of $47,784.00.
• On Friday, June 13th, Scott Lish sold 22,727 shares of Alphatec stock. The shares were sold at an average price of $11.07, for a total value of $251,587.89.
• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The stock was sold at an average price of $13.00, for a total transaction of $719,875.00.

Alphatec Price Performance

Shares of NASDAQ ATEC traded up $0.13 during midday trading on Friday, reaching $15.70. 1,804,563 shares of the company traded hands, compared to its average volume of 2,076,673. The firm has a market cap of $2.32 billion, a PE ratio of -13.89 and a beta of 1.05. The stock's 50-day simple moving average is $11.88 and its 200-day simple moving average is $11.40. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $16.01. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The business's revenue was up 27.5% on a year-over-year basis. During the same period last year, the business earned ($0.29) earnings per share. As a group, equities analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Captrust Financial Advisors raised its holdings in shares of Alphatec by 337.5% in the second quarter. Captrust Financial Advisors now owns 49,195 shares of the medical technology company's stock valued at $546,000 after buying an additional 37,950 shares during the last quarter. Manatuck Hill Partners LLC bought a new position in shares of Alphatec in the second quarter valued at about $777,000. Engineers Gate Manager LP raised its holdings in shares of Alphatec by 64.4% in the second quarter. Engineers Gate Manager LP now owns 347,339 shares of the medical technology company's stock valued at $3,855,000 after buying an additional 136,006 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Alphatec by 14.9% in the second quarter. Cubist Systematic Strategies LLC now owns 879,817 shares of the medical technology company's stock valued at $9,766,000 after buying an additional 113,963 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of Alphatec by 161.1% in the second quarter. BNP Paribas Financial Markets now owns 613,478 shares of the medical technology company's stock valued at $6,810,000 after buying an additional 378,553 shares during the last quarter. 66.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ATEC shares. Needham & Company LLC restated a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a research note on Friday, May 2nd. Wall Street Zen raised Alphatec from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 target price for the company in a research report on Monday, June 16th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research report on Friday, August 1st. Finally, Barclays reaffirmed an "overweight" rating and issued a $22.00 target price (up from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $18.50.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.